Fujifilm Holdings Corp · TSE:4901
Fujifilm — FY2024 Earnings Presentation
41 slides from Fujifilm's earnings presentation, May 8, 2025
Slide 1: Earnings Presentation: Financial Results for FY2024
Earnings Presentation Financial Results for FY2024 May 8, 2025 Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are manage ment’s current assumptions and beliefs based on currently available information. Such forward-looking s
Slide 2: Agenda
Agenda FY2024 (Fiscal Year Ended March 2025) Earnings Highlights and Key Topics 1 Teiichi Goto, President, Representative Director & CEO FUJIFILM Holdings Corporation 2 Financial Results and Business Summary by Operating Segment Masayuki Higuchi, Director & Corporate Vice President, CFO FUJIFILM Hol
Slide 3: FY2024 Earnings Highlights and Key Topics
Earnings Highlights FY2024 FY2025 Forecast Appendices FY2024 Earnings Highlights and Key Topics 01 FUJIFILM Holdings Corporation 3
Slide 4: Earnings Highlights for FY2024
Highlights Key Topics FY2024 (Fiscal Year Earnings Highlights FY2024 FY2025 Forecast Appendices Ending March 2025) Earnings Highlights for FY2024 Consolidated Performance for FY2024 (Exchange rates for FY2024: ¥152/US$ +¥7 YoY; ¥164/Euro +¥7 YoY) Revenue Operating income Net income (Operating margin
Slide 5: Highlights of Financial Forecast for FY2025
Earnings Highlights Highlights Key Topics FY2024 FY2025 Forecast Appendices Highlights of Financial Forecast for FY2025 Full-year Forecast for FY2025 (Exchange rates for FY2025: ¥145/US$ -¥7 YoY; ¥155/Euro -¥9 YoY) Revenue Operating income Net income attributable to FUJIFILM Holdings Record high Rec
Slide 6: Shareholder Returns
Highlights Key Topics FY2024 (Fiscal Year Earnings Highlights FY2024 FY2025 Forecast Appendices Ending March 2025) Shareholder Returns • The annual dividends for FY2024 are planned to be ¥65 per share, which is ¥5 higher than the previous annual forecast of ¥60 • The annual dividends for FY2025 are
Slide 7: Key Topics 1: Growth Initiatives for FY2025 1/2 Bio CDMO
Highlights Key Topics FY2024 (Fiscal Year Earnings Highlights FY2024 FY2025 Forecast Appendices Ending March 2025) Key Topics ❶: Growth Initiatives for FY2025 1/2 Bio CDMO Negotiations for large-scale facilities at the Denmark and U.S. sites are steadily progressing. On track to achieve its FY2026 r
Slide 8: Key Topics 1: Growth Initiatives for FY2025 2/2 Semiconductor Materials
Earnings Highlights Highlights Key Topics FY2024 FY2024 FY2025 Forecast Appendices Key Topics ❶: Growth Initiatives for FY2025 2/2 Semiconductor Materials Supporting Tata Electronics Private Limited (“Tata”) for establishment of a semiconductor materials ecosystem in India. Aiming to officially ente
Slide 9: Key Topics 2: Initiatives toward Sustainability
Earnings Highlights Highlights Key Topics FY2024 FY2025 Forecast Appendices Key Topics ❷: Initiatives toward Sustainability New External Acknowledgement Under the Fujifilm Group Purpose "Giving our world more smiles," we will contribute further to the realization of a sustainable society by enhancin
Slide 10: FY2024 Financial Results and Business Summary by Operating Segment
Earnings Highlights FY2024 FY2025 Forecast Appendices FY2024 Financial Results and Business Summary by Operating Segment 02 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from figures
Slide 11: Financial Results for FY2024
Earnings Highlights FY2024 Company-wide By Segment CF FY2025 Forecast Appendices Financial Results for FY2024 (Billions of yen) Q4 Full Year Impact of Constant- Impact of Constant- FY2023 FY2024 Change FY2023 FY2024 Change exchange rate currency basis exchange rate currency basis Revenue 805.5 Recor
Slide 12: Consolidated Revenue and Operating Income by Operating Segment
Earnings Highlights FY2024 Company-wide By Segment CF FY2025 Forecast Appendices FY2024 (Fiscal Year Ended March 2025) Consolidated Revenue and Operating Income by Operating Segment (Billions of yen) Q4 Full Year Revenue FY2023 FY2024 Change FY2023 FY2024 Change Constant-currency basis Constant-curr
Slide 13: Business Summary: Healthcare
Earnings Highlights FY2024 Company-wide By Segment CF FY2025 Forecast Appendices FY2024 (January to March 2025) Business Summary: Healthcare YoY Change Revenue increased driven by strong sales of medical IT, endoscope and others in Medical Systems, as Revenue Operating income well as contributions f
Slide 14: Business Summary: Electronics
Earnings Highlights FY2024 Company-wide By Segment CF FY2025 Forecast Appendices FY2024 (January to March 2025) Business Summary: Electronics YoY Change Revenue increased as we successfully tapped into demand for advanced semiconductor materials, Revenue Operating income such as those for generative
Slide 15: Business Summary: Business Innovation
Earnings Highlights FY2024 Company-wide By Segment CF FY2025 Forecast Appendices FY2024 (January to March 2025) Business Summary: Business Innovation YoY Change Revenue rose mainly due to higher sales of digital transformation (DX)-related solutions in Business Revenue Operating income Solutions and
Slide 16: Business Summary: Imaging
Earnings Highlights FY2024 Company-wide By Segment CF FY2025 Forecast Appendices FY2024 (January to March 2025) Business Summary: Imaging YoY Change Revenue Operating income Revenue and profit soared due to strong sales of instant photo systems and digital cameras. ↑+14.1％ ↑+1.9times 115.3 (Billions
Slide 17: Consolidated Cash Flows and Adjusted Free Cash Flow
Earnings Highlights FY2024 Company-wide By Segment CF FY2025 Forecast Appendices FY2024 (April 2024 to March 2025) Consolidated Balance Sheets Cash in Cash out Adjusted free cash flow excluding business acquisitions (Billions of yen) (Billions of yen) FY2022 FY2023 FY2024 Full Year Full Year Full Ye
Slide 18: Financial Forecast for FY2025
Earnings Highlights FY2024 FY2025 Forecast Appendices Financial Forecast for FY2025 03 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from figures published in the past, and in some ca
Slide 19: Full-year Forecast for FY2025 (Excluding U.S. Tariff Impact)
Earnings Highlights FY2024 FY2025 Forecast Appendices Full-year Forecast for FY2025 (Excluding the Impact of the U.S. Tariff Policy) (Billions of yen) FY2024 FY2025 Change from Actual forecast FY2024 Revenue 3,195.8 Record high 3,280.0 84.2 100.0% 100.0% +2.6% Operating Income 330.2 Record high 331.
Slide 20: Financial Forecast by Operating Segment
Earnings Highlights FY2024 FY2025 Forecast Appendices Financial Forecast by Operating Segment (Excluding the Impact of the U.S. Tariff Policy) Total revenue of ¥3,280.0 billion is forecast for FY2025, with the launch of new large-scale facilities at Bio CDMO expected to be a major driving force.Oper
Slide 21: Impact of the U.S. Tariff Policy
Earnings Highlights FY2024 FY2025 Forecast Appendices Impact of the U.S. Tariff Policy In response to the U.S. tariff policy, the Company will pay close attention to future dynamics and take swift and necessary measures — such as reviewing our supply chain, further reducing expenses, and revising ou
Slide 22: ROIC (Return on Invested Capital)
Earnings Highlights FY2024 FY2025 Forecast Appendices ROIC (Return on Invested Capital) In FY2024, ROIC was 5.9%, up 0.3 pt YoY, driven primarily by improvements mainly in Electronics and Imaging. In FY2025, ROIC is planned to decline by 0.4 pt to 5.5% as we continue to make growth investments in He
Slide 23: Cash Allocation (FY2025 Forecast)
Earnings Highlights FY2024 FY2025 Forecast Appendices Cash Allocation (FY2025 Forecast) Capital expenditure in Healthcare, primarily Bio CDMO, peaked in FY2024, but the Company continues to make growth investments, mainly in Healthcare and Electronics, in FY2025. Interest-bearing Shareholder returns
Slide 24: Management Conscious of Cost of Capital and Stock Price
Earnings Highlights FY2024 FY2025 Forecast Appendices Implement Management that Is Conscious of Cost of Capital and Stock Price Aiming to achieve an ROE of 10% or higher in FY2030 by continuously striving to improve ROIC across all business segments, while also contributing to the sustainable enhanc
Slide 25: Shareholder Returns
Earnings Highlights FY2024 FY2025 Forecast Appendices Shareholder Returns ▐ Dividend trends (forecast) ▐ Policy on shareholder returns Annual dividend for FY2024 : ¥65 per share 70 ¥ Annual dividend for FY2025 : ¥70 per share 65 Share price (¥) 6,000 16th consecutive ¥ Ensure a balance between busin
Slide 26: Appendices: Financial Results for FY2024
Earnings Highlights FY2024 FY2025 Forecast Appendices Appendices: Financial Results for FY2024 04 * From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from figures published in the past, and
Slide 27: Q4 / Full-year (12 months) Earnings
Earnings Highlights FY2024 FY2024 Forecast FY2025 Appendices Q4 / Full-year (12 months) Earnings (Billions of yen) Q4 Full Year Revenue FY2023 FY2024 Change FY2023 FY2024 Change Constant-currency basis Constant-currency basis Healthcare 284.4 310.0 25.6 +9.0% 22.1 +7.8% 975.1 1,022.6 47.5 +4.9% 17.0
Slide 28: Quarterly Earnings
Earnings Highlights FY2024 FY2024 Forecast FY2025 Appendices Quarterly Earnings (Billions of yen) FY2023 FY2024 Revenue Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Healthcare 206.8 241.4 242.5 284.4 229.2 242.9 240.5 310.0 Medical Systems 140.1 164.6 164.7 190.2 157.7 166.9 162.6 206.1 Bio CDMO 40.9 50.5 50.3 61.8 47.1
Slide 29: Consolidated Revenue by Geographical Area
Earnings Highlights FY2024 FY2025 Forecast Appendices Consolidated Revenue by Geographical Area (Billions of yen) FY2023 Full Year FY2024 Full Year Change Ratio (%) Ratio (%) Japan 35.4% 1,049.6 34.4% 1,099.3 49.8 +4.7% The Americas 21.7% 641.8 20.2% 646.9 5.1 +0.8% Europe 15.9% 470.6 17.0% 544.6 74
Slide 30: Operating Income Analysis (Q4 YoY)
Earnings Highlights FY2024 FY2024 Forecast FY2025 Appendices Operating Income Analysis (Q4 YoY) (Billions of yen) Q4 (a) (b) FY2023 FY2024 Operation Raw Material （b-a) Operating Change FX FY2023 FY2024 Detail Actual Actual and others price One-time cost Q4 Q4 Segment Healthcare 37.1 44.8 7.7 (10.7)
Slide 31: Operating Income Analysis (FY2024 Results vs Previous Forecast)
Earnings Highlights FY2024 FY2024 Forecast FY2025 Appendices Operating Income Analysis (FY2024 Results vs Previous Forecast) (Billions of yen) Previous FY2024 (a) (b) forecast Operation Raw Material （b-a) Operating Actual Change FX Previous FY2024 Detail (Feb 6,2025) and others price One-time cost f
Slide 32: Bio CDMO Profitability
Earnings Highlights FY2024 FY2025 Forecast Appendices Bio CDMO Profitability (Q4 YoY; FY2024 Forecast vs FY2023 Results) EBITDA margin for FY2024 Q4 was in the low 10% range. In FY2025, despite higher fixed costs associated with the launch of new large-scale facilities in Denmark and the U.S., the E
Slide 33: Full-year Forecast for FY2025 Revenue by Business
Earnings Highlights FY2024 FY2024 Forecast FY2025 Appendices Full-year Forecast for FY2025 Revenue by Business FY2024 FY2025 Change from previous year With Constant currency Actual Forecast Amount of money currency impact basis Healthcare 1,047.8 1,100.0 52.2 +5.0% +8.3% Medical Systems 693.2 700.0
Slide 34: Operating Income Analysis (FY2025 Forecast vs FY2024 Results)
Earnings Highlights FY2024 FY2024 Forecast FY2025 Appendices Operating Income Analysis (FY2025 Forecast vs FY2024 Results) (Billions of yen) FY2024 FY2025 Operation Raw Material （b-a) (a) (b) Operating Actual Forecast Change FX FY2024 FY2025 Detail and others price One-time cost Actual Forecast Segm
Slide 35: Consolidated Balance Sheets
Earnings Highlights FY2024 FY2024 Forecast FY2025 Appendices FY2024 (Fiscal Year Ending March 2025) Consolidated Balance Sheets (Billions of yen) Change from Change from Mar. 2023 Mar. 2024 Mar. 2025 Mar. 2023 Mar. 2024 Mar. 2025 Mar. 2024 Mar. 2024 Cash and cash equivalents 268.6 179.7 172.1 (7.6)
Slide 36: Capital Expenditure and Depreciation & Amortization
Earnings Highlights FY2024 FY2025 Forecast Appendices Capital Expenditure and Depreciation & Amortization Capital Expenditure and Depreciation & Amortization *1 *2 (Billions of yen) ▐ Former segment basis: Until FY2024 ▐ New segment basis: From FY2025 6,000 600.0 532.1 (Billions of yen) Q4 Full Year
Slide 37: R&D Expenses and SG&A Expenses
Earnings Highlights FY2024 FY2025 Forecast Appendices R&D Expenses and SG&A Expenses *1 *2 (Billions of yen) ▐ Former segment basis: Until FY2024 ▐ New segment basis: From FY2025 R&D Expenses｜SG&A Expenses Ratio to revenue 900.0 9,000 40.0% 806.5 (Billions of yen) 752.5 Q4 Full Year FullYear 30.0% F
Slide 38: Market Trend and Number of Employees
Earnings Highlights FY2024 FY2025 Forecast Appendices Market Trend and Number of Employees ▐ Exchange rates (average) / Raw material prices (average) FY2023 FY2024 Unit Q1 Q2 Q3 Q4 Full Year Q1 Q2 Q3 Q4 Full Year US$ ¥US/$ 138 145 148 149 145 156 149 152 152 152 € ¥/€ 150 157 159 161 157 168 164 163
Slide 39: References
Earnings Highlights FY2024 FY2025 Forecast Appendices References ▍ FUJIFILM Holdings - Investor Relations https://ir.fujifilm.com/en/investors.html ▍ FUJIFILM Holdings Integrated Report https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html ▍ IR Materials https://ir.fujifilm.com/en
Slide 40: FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation
Slide 41: FUJIFILM: Value from Innovation
FUJIFILM Value from Innovation